GP 1653 #7

PATENT

Case Docket No. VANMA48.001CP1
Date: January 9, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Laub, et al.
Appl. No.	:	09/853,080
Filed	:	May 9, 2001
For	:	ANTIGENIC POLYPEPTIDE SEQUENCES OF FACTOR VIII, AND FRAGMENTS AND/OR EPITOPES OF THESE SEQUENCES
Examiner	:	Unknown
Group Art Unit	:	1653

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

January 9, 2002
(Date)

Daniel Hart
Daniel Hart, Reg. No. 40,637

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with twenty-eight (28) references.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Daniel Hart
Daniel Hart
Registration No. 40,637
Attorney of Record

O:\DOCS\MCM\MCM-1675.DOC:vb
120401

IDS #7
2/2/02

VANMA48.001CP1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Laub, et al.	)	Group Art Unit 1653
App. No.	:	09/853,080	)	
Filed	:	May 9, 2001	)	
For	:	ANTIGENIC POLYPEPTIDE SEQUENCES OF FACTOR VIII, AND FRAGMENTS AND/OR EPITOPES OF THESE SEQUENCES	)	
Examiner	:	Unknown	)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing twenty-eight (28) references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 9, 2002

By: Daniel Hart

Daniel Hart
Registration No. 40,637
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

O:\DOCS\MCM\MCM-1676.DOC:vb 120401

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VANMA48.001CP1	APPLICATION NO. 09/853,080
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Laub, et al.	
	FILING DATE May 9, 2001	GROUP 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1.	Algiman, M., et al. (1992) Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc. Natl. Acad. Sci. USA 89:3795-3799.
	2.	Dietrich, G., et al. (1992) Origin of Anti-idiotypic Activity Against Anti-factor VIII Autoantibodies in Pools of Normal Human Immunoglobulin G (IVIg). Blood 79:2946-2951.
	3.	Ewenstein, B. M., et al. (2000) Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 85 (Suppl. 10):35-39.
	4.	Foster, P. A. and Zimmerman, T. S. (1989) Factor VIII Structure and Function. Blood Reviews 3:180-191.
	5.	Janin, J. (1979) Surface and inside volumes in globular proteins. Nature 277:491-492.
	6.	Karplus, P. A. and Schulz, G. E. (1985) Prediction of Chain Flexibility in Proteins. Naturwissenschaften 72:212-213.
	7.	Knobl, P. and Derfler, K. (1999) Extracoporeal Immunoadsorption for the Treatment of Haemophilic Patients with Inhibitors to Factor VIII or IX. Vox Sanguinis 77 (Suppl. 1):57-64.
	8.	Laub, R., et al. (1999) Inhibitors in German Hemophilia A Patients Treated with a Double Virus Inactivated Factor VIII Concentrate Bind to the C2 Domain in FVIII Light Chain. Thromb. Haemost. 81:39-44.
	9.	Lollar, P. (2000) Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 85 (Suppl. 10):26-30.
	10.	Moreau, A., et al. (2000) Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 95:3435-3441.
	11.	Morrisson, A. E. and Ludlam C. A. (1995) Acquired Haemophilia and its Management. Br. J. Haematol. 89:231-236.
	12.	Palmer, D. S., et al. (1997) Identification of Novel Factor VIII Inhibitor Epitopes using Synthetic Peptide Arrays. Vox Sanguinis 72:148-161.
	13.	Parker, J. M. R., et al. (1986) New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites. Biochem. 25:5425-5432.
	14.	Peerlinck, K., et al. (1997) Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate. Throm. Haemost. 77:80-86.

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VANMA48.001CP1	APPLICATION NO. 09/853,080
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Laub, et al.	
	FILING DATE May 9, 2001	GROUP 1653

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	15.	Pemberton, S., et al. (1997) A Molecular Model for the Triplicated A Domains of Human Factor VIII Based on the Crystal Structure of Human Ceruloplasmin. Blood 89(7):2413-2421.
	16.	Pratt, K. P. (2000) Relating structure to function: The role of the C2 domain in Factor VIII. Curr. Opinion Drug Discovery & Development 3(5):516-526.
	17.	Raut, S., et al. (1998) Modification of Factor VIII in Therapeutic Concentrates after Virus Inactivation by Solvent-Detergent and Pasteurisation. Throm. Haemost. 80:624-631.
	18.	Reding, M. T., et al. (2000) Sensitization of $CD4^+$ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects. Thromb. Haemost. 84:643-652
	19.	Reisner, H. M., et al. (1995) Immunogentics of the human immune response to factor VIII. Aledort, L. M., et al., eds. Inhibitors to Coagulation Factors. New York, NY: Plenum Press pp 65-78.
	20.	Saenko, E. L., et al. (1999) Role of Activation of the Coagulation Factor VIII in Interaction with vWf, Phospholipid, and Functioning within the Factor Xase Complex. TCM 9:185-192.
	21.	Scandella, D. H. (2000) Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients. Semin. Thromb. Haemost. 26(2):137-142.
	22.	Shima, M., et al. (1991) Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Williebrand factor. Intl. J. Haematol. 54:515-522.
	23.	Toole, J. J., et al. (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312:342-347.
	24.	Tuddenham, E. G. D. and McVey, J. H. (1998) The genetic basis of inhibitor development in haemophilia A. Haemophilia 4:543-545.
	25.	van den Brink, E. N., et al. (2000) Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 95(2):558-563.
	26.	Van Regenmortel, M. H. V. (1996) Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensional Description of Antigenic Specificity. Methods: A Companion to Methods in Enzymology 9:465-472.
	27.	Vehar, G. A., et al. (1984) Structure of human factor VIII. Nature 312:337-342.
	28.	Vermylen, J. (1998) How do some haemophiliacs develop inhibitors? Hemophilia 4:538-542.

O:\DOCS\MCM\MCM-1677.DOC:vb
120401

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.